Dermatology medications with the highest cost burden on Medicare Part D: Potential implications of the Inflation Reduction Act.
J Am Acad Dermatol
; 91(2): 379-381, 2024 Aug.
Article
in En
| MEDLINE
| ID: mdl-38663745
ABSTRACT
Signed into law in August 2022, the Inflation Reduction Act includes provisions requiring the federal government to negotiate prices for medications covered under Medicare Part D. Initial negotiations will target drugs with the highest total spending and price increases relative to inflation. In this study, we identify dermatology prescriptions with the highest cost burden on Medicare Part D and analyze recent trends in total spending and unit costs.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Drug Costs
/
Dermatologic Agents
/
Medicare Part D
Limits:
Humans
Country/Region as subject:
America do norte
Language:
En
Journal:
J Am Acad Dermatol
Year:
2024
Document type:
Article